These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 39412805)

  • 1. Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Granted Breakthrough Therapy Designation in China, 2020-2024.
    Luo X; Du X; Lv X; Yang Y; Zhang X; Huang L
    JAMA Netw Open; 2024 Oct; 7(10):e2439080. PubMed ID: 39412805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price.
    Michaeli DT; Michaeli T
    J Natl Compr Canc Netw; 2024 Apr; 22(4):. PubMed ID: 38648855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.
    Michaeli JC; Michaeli T; Trapani D; Albers S; Dannehl D; Würstlein R; Michaeli DT
    Breast Cancer; 2024 Nov; 31(6):1144-1155. PubMed ID: 39320645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis.
    Luo X; Du X; Huang L; Guo Q; Tan R; Zhou Y; Li Z; Xue X; Li T; Le K; Qian F; Chow SC; Yang Y
    Lancet Reg Health West Pac; 2023 Mar; 32():100670. PubMed ID: 36785854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis.
    Jenei K; Gentilini A; Haslam A; Prasad V
    Lancet Oncol; 2024 Aug; 25(8):979-988. PubMed ID: 39004098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines.
    Hwang TJ; Franklin JM; Chen CT; Lauffenburger JC; Gyawali B; Kesselheim AS; Darrow JJ
    J Clin Oncol; 2018 Jun; 36(18):1805-1812. PubMed ID: 29688832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Launch Price and Clinical Value With Reimbursement Decisions for Anticancer Drugs in China.
    Zhou J; Lu H; Pan J
    Int J Health Policy Manag; 2024; 13():8150. PubMed ID: 38618837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
    Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
    Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022.
    Luo X; Du X; Huang L; Guo Q; Lv X; Wang C; Liu H; Zhou Y; Xue X; Li Z; Liu J; Chow SC; Yang Y
    EClinicalMedicine; 2023 Sep; 63():102177. PubMed ID: 37662522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
    Michaeli T; Jürges H; Michaeli DT
    BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
    Chen EY; Raghunathan V; Prasad V
    JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
    Chen EY; Joshi SK; Tran A; Prasad V
    JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.
    Trotta F; Mayer F; Barone-Adesi F; Esposito I; Punreddy R; Da Cas R; Traversa G; Perrone F; Martini N; Gyawali B; Addis A
    BMJ Open; 2019 Dec; 9(12):e033728. PubMed ID: 31826897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
    Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
    Eur J Health Econ; 2024 Aug; 25(6):979-997. PubMed ID: 37962724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
    Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
    JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending.
    Michaeli T; Michaeli DT
    Value Health; 2024 Apr; 27(4):449-457. PubMed ID: 38244983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the breakthrough-therapy-designated drugs granted in China: A pooled analysis 2020-2022.
    Luo X; Qian F; Yang L; Li Y; Yang Y
    Drug Discov Today; 2022 Dec; 27(12):103370. PubMed ID: 36154876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.